AstraZeneca’s Q3 Results Fuel Optimism for Continued Growth

AstraZeneca (LON: AZN) has reported a robust performance for the third quarter and nine months of 2025, exceeding expectations and bolstering confidence in its long-term growth trajectory.

The pharmaceutical giant's strong commercial execution and pipeline advancements have set a positive tone, paving the way for sustained expansion through 2026 and beyond.

Headline Numbers: Revenue: Total revenue for the first nine months of 2025 reached $43.236 billion, a 10% increase (11% at constant exchange rates or CER). Q3 2025 revenue stood at $15.191 billion, up 12% (10% at CER).
EPS: Reported earnings per share (EPS) for 9M 2025 were $5.10, a 43% increase, while Q3 2025 EPS surged 77% to $1.64. Core EPS for 9M 2025 rose 15% to $7.04, with Q3 2025 Core EPS increasing 14% to $2.38.

The company's strategic focus on high-growth areas, particularly oncology and biopharmaceuticals, is yielding notable returns. Oncology revenue grew by 16%, and revenue from the R&I (Research and Innovation) segment increased by 13%, both at constant exchange rates.

Pascal Soriot, Chief Executive Officer of AstraZeneca, stated, “The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition.” reinforcing the company’s growth strategy.

AstraZeneca has reiterated its full-year 2025 guidance, expecting total revenue to increase by a high single-digit percentage and Core EPS to increase by a low double-digit percentage, both at constant exchange rates. The company expects its Core Tax rate to be between 18-22%.